Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2022 Filed Jul 14, 2022 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-019304 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,013 Underlying: Common Stock · 21,500 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| July 14, 2022 Filed Jul 14, 2022 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 21,500 | $43.43 | $933,745.00 |
DisclosureSEC source: 0001127602-22-019304 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,346 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| July 14, 2022 Filed Jul 14, 2022 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 21,500 | $9.65 | $207,475.00 |
DisclosureSEC source: 0001127602-22-019304 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| June 13, 2022 Filed Jun 16, 2022 01:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 47,745 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001140361-22-023152 · form4.xml · derivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 Underlying: Common Stock · 47,745 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-017235 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,513 Underlying: Common Stock · 21,500 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 21,500 | $40.62 | $873,330.00 |
DisclosureSEC source: 0001127602-22-017235 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,346 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 21,500 | $9.65 | $207,475.00 |
DisclosureSEC source: 0001127602-22-017235 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| May 12, 2022 Filed May 12, 2022 21:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 13,987 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001061983-22-000125 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,987 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| May 12, 2022 Filed May 12, 2022 21:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 13,987 | $37.54 | $525,074.78 |
DisclosureSEC source: 0001061983-22-000125 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,084 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| May 12, 2022 Filed May 12, 2022 21:52 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 13,987 | $9.65 | $134,974.55 |
DisclosureSEC source: 0001061983-22-000125 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| April 07, 2022 Filed Apr 7, 2022 21:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 23,148 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000097 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,148 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| April 07, 2022 Filed Apr 7, 2022 21:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 23,148 | $42.58 | $985,755.27 |
DisclosureSEC source: 0001061983-22-000097 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,084 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| April 07, 2022 Filed Apr 7, 2022 21:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 23,148 | $6.00 | $138,888.00 |
DisclosureSEC source: 0001061983-22-000097 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 00:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 26,852 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000075 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,852 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 00:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 26,852 | $37.82 | $1,015,462.08 |
DisclosureSEC source: 0001061983-22-000075 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,084 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 00:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 26,852 | $6.00 | $161,112.00 |
DisclosureSEC source: 0001061983-22-000075 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 00:14 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 8,641 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001140361-22-009222 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,641 Underlying: Common Stock · 8,641 shares Expires 2032-03-10 F2 · derivative.exercise_date: This option represents a right to purchase a total of 8,641 shares of the Issuer's common stock, which will fully vest on March 10, 2024. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 00:14 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 33,199 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001140361-22-009222 · form4.xml · derivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,199 Underlying: Common Stock · 33,199 shares Expires 2032-03-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 33,199 shares of the Issuer's common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on March 10, 2025. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 23:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 9,916 | $36.83 | $365,206.28 |
DisclosureSEC source: 0001061983-22-000069 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,084 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/07/2022 and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 66,621 | $37.63 Strike: $37.63 | $2,506,948.23 |
DisclosureSEC source: 0001061983-22-000055 · edgardoc.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,621 Underlying: Common Stock · 66,621 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 3,379 | $37.63 Strike: $37.63 | $127,151.77 |
DisclosureSEC source: 0001061983-22-000055 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,379 Underlying: Common Stock · 3,379 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000055 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,000 F2 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 5,004 | $37.63 | $188,300.52 |
DisclosureSEC source: 0001061983-22-000055 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/02/2022 and does not represent a sale by the reporting person. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 00:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 3,458 | $35.32 | $122,136.56 |
DisclosureSEC source: 0001061983-22-000039 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,004 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2022 and does not represent a sale by the reporting person. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000027 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,462 F2 · kind: Comprised of restricted stock units (RSUs) issued upon conversion of certain PSUs granted to the Reporting Person on May 11, 2021. The satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into RSUs of the Issuer. These RSUs will vest in whole on February 16, 2023. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000027 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,087 F1 · kind: On or about May 11, 2021, the Reporting Person was granted performance-based stock units (PSUs) of the Issuer, which upon satisfaction and certification of the performance metric resulted in a portion of the PSUs being converted into fully-vested shares of common stock of the Issuer. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,427 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001061983-21-000263 · edgardoc.xml · derivative · entry 6 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,427 shares Expires 2022-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 22,739 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001061983-21-000263 · edgardoc.xml · derivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,739 shares Expires 2022-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 22,739 | $36.49 | $829,762.03 |
DisclosureSEC source: 0001061983-21-000263 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,314 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,436 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 22,739 | $6.30 | $143,255.70 |
DisclosureSEC source: 0001061983-21-000263 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,436 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 6,427 | $36.49 | $234,525.73 |
DisclosureSEC source: 0001061983-21-000263 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,314 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,436 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 6,427 | $6.30 | $40,490.10 |
DisclosureSEC source: 0001061983-21-000263 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,436 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $39.56 | $79,120.00 |
DisclosureSEC source: 0001061983-21-000257 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,878 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,000 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| October 14, 2021 Filed Oct 14, 2021 21:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $37.73 | $75,452.20 |
DisclosureSEC source: 0001061983-21-000235 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,878 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,000 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| September 09, 2021 Filed Sep 9, 2021 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $31.43 | $62,860.00 |
DisclosureSEC source: 0001061983-21-000212 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,878 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,000 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 21:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $32.60 | $65,200.00 |
DisclosureSEC source: 0001061983-21-000204 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,878 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,000 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 21:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $19.48 | $38,952.20 |
DisclosureSEC source: 0001061983-21-000193 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,878 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,000 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 20:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $21.48 | $42,951.60 |
DisclosureSEC source: 0001061983-21-000158 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,878 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 2,000 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| May 13, 2021 Filed May 14, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $24.42 | $48,840.00 |
DisclosureSEC source: 0001061983-21-000140 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,348 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| April 08, 2021 Filed Apr 8, 2021 22:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $23.39 | $46,772.40 |
DisclosureSEC source: 0001061983-21-000106 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,348 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| March 11, 2021 Filed Mar 11, 2021 21:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $19.90 | $39,798.00 |
DisclosureSEC source: 0001061983-21-000081 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,348 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 23:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 7,634 | $19.19 | $146,496.46 |
DisclosureSEC source: 0001061983-21-000077 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,348 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/06/2021 and does not represent a sale by the reporting person. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 49,694 | $19.42 Strike: $19.42 | $965,057.48 |
DisclosureSEC source: 0001061983-21-000060 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,694 Underlying: Common Stock · 49,694 shares Expires 2031-03-01 F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 10,306 | $19.42 Strike: $19.42 | $200,142.52 |
DisclosureSEC source: 0001061983-21-000060 · edgardoc.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,306 Underlying: Common Stock · 10,306 shares Expires 2031-03-01 F3 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000060 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,982 F1 · kind: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 00:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,767 | $19.66 | $54,399.22 |
DisclosureSEC source: 0001061983-21-000050 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,982 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 03/01/2021 and does not represent a sale by the reporting person. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 22:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 7,060 | $18.73 | $132,233.80 |
DisclosureSEC source: 0001061983-21-000042 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,749 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2021 and does not represent a sale by the reporting person. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 22:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,632 | $23.34 | $38,097.08 |
DisclosureSEC source: 0001061983-21-000028 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,809 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 617 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001061983-21-000020 · edgardoc.xml · derivative · entry 6 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 617 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,883 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001061983-21-000020 · edgardoc.xml · derivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,883 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.